TEVA Stoklara Genel Bakış Teva Pharmaceutical Industries Limited, Kuzey Amerika, Avrupa, İsrail ve uluslararası alanda jenerik ilaçlar, özel ilaçlar ve biyofarmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dağıtmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Teva Pharmaceutical Industries Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Teva Pharmaceutical Industries Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$7.85 52 Haftanın En Yüksek Seviyesi US$0 52 Haftanın En Düşük Seviyesi US$0 Beta 0.87 1 Aylık Değişim 0% 3 Aylık Değişim 0% 1 Yıllık Değişim 0% 3 Yıllık Değişim 0% 5 Yıllık Değişim 0% Halka arzdan bu yana değişim -85.75%
Son Haberler & Güncellemeler
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept) Feb 18 Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2025
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01 Daha fazla güncelleme görün
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept) Feb 18 Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2025
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.78 loss in 2Q 2023) Aug 02 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18
Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses Jun 29
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States Jun 25
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 30
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 May 16 Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023) May 08 Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China Apr 11
Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024 Apr 10
Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022) Feb 01
Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Feb 01
Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024 Jan 31
Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents Jan 02
Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity Dec 06
Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022) Nov 10
Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business Nov 08
Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Oct 17
Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 07
Teva Announces Changes to Executive Management Team Sep 29
Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023 Aug 05
Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022) Aug 04 Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023 Jul 28 Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023
Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study Jul 01
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY Jun 17 Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023 Jun 03
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 21
Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States May 16
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022) May 11
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023 May 11
Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021) Feb 10
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023 Feb 09
Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023 Jan 13
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Dec 06 Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023
Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021) Nov 05 Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022
Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims Oct 08 Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022 Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression
Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc Sep 03
Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries Aug 29
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Jul 29
Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022 Jul 28
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021) Jul 27
Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer Jul 02
Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022 Jun 30 Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia May 18
Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022
First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021) May 03
Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022 Apr 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 10
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Feb 10
Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S Dec 23
Chief Accounting Officer Andrew Weil has left the company Dec 01
Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020) Oct 28
Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims Oct 01
Forecast to breakeven in 2021 Sep 23
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Executive Vice President of North America Commercial Brendan O'Grady has left the company Aug 18
Insufficient new directors Aug 01
Second quarter 2021 earnings released: EPS US$0.19 (vs US$0.13 in 2Q 2020) Jul 30
Independent Director Abbas Hussain has left the company Jul 15
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults Jun 24
Teva Announces Its Launch of the First Generic Perforomist®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States Jun 23 Teva Pharmaceutical Industries Ltd. Presents Analysis on AJOVY® (fremanezumab) Injection
Executive Vice President of International Markets Commercial Gianfranco Nazzi has left the company May 01
Teva Pharmaceutical Industries Limited Announces the Launch of the First Generic Version of Absorica (Isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States Apr 30
First quarter 2021 earnings released: EPS US$0.07 (vs US$0.063 in 1Q 2020) Apr 29
Teva Pharmaceutical Industries Limited Reaffirms Its Earnings Guidance for the Year 2021 Apr 29 Hissedar Getirileri TEVA CH Pharmaceuticals CH Pazar 7D 0% 1.6% 0.6% 1Y 0% 18.6% 10.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: TEVA geçen yıl % 18.6 oranında getiri sağlayan Swiss Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: TEVA geçen yıl % 10.2 oranında getiri sağlayan Swiss Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is TEVA's price volatile compared to industry and market? TEVA volatility TEVA Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 3.0% Market Average Movement 3.6% 10% most volatile stocks in CH Market 7.9% 10% least volatile stocks in CH Market 1.7%
İstikrarlı Hisse Senedi Fiyatı: TEVA hisse senedi fiyatı, son 3 ayda Swiss piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: TEVA 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Teva Pharmaceutical Industries Limited, Kuzey Amerika, Avrupa, İsrail ve uluslararası alanda jenerik ilaçlar, özel ilaçlar ve biyofarmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve dağıtmaktadır. Tabletler, kapsüller, enjektabllar, inhalantlar, sıvılar, transdermal bantlar, merhemler ve kremler gibi çeşitli dozaj formlarında jenerik ilaçlar; parenteral ve katı dozaj formlarında steril ürünler, hormonlar, yüksek potensli ilaçlar ve sitotoksik maddeler; ve tıbbi cihazlar ve kombinasyon ürünleri ile jenerik ürünler sunmaktadır. Şirket, merkezi sinir sistemi (MSS), solunum ve onkoloji alanlarına odaklanmaktadır.
Daha fazla göster Teva Pharmaceutical Industries Limited Temel Bilgiler Özeti Teva Pharmaceutical Industries'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? TEVA temel i̇stati̇sti̇kler Piyasa değeri CHF 16.54b Kazançlar(TTM ) -CHF 851.86m Gelir(TTM ) CHF 14.90b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) TEVA gelir tablosu (TTM ) Gelir US$16.77b Gelir Maliyeti US$8.41b Brüt Kâr US$8.36b Diğer Giderler US$9.32b Kazançlar -US$959.00m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.85 Brüt Marj 49.84% Net Kâr Marjı -5.72% Borç/Özkaynak Oranı 297.3%
TEVA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/11/17 17:06 Gün Sonu Hisse Fiyatı 2024/08/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Teva Pharmaceutical Industries Limited 59 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Jasper Hellweg Argus Research Company Balaji Prasad Barclays Balaji Prasad Barclays
Göster 56 daha fazla analist 
